TY - STD TI - Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.1, Cancer incidence and mortality worldwide: IARC CancerBase no. 11. Lyon, France: International Agency for Research on Cancer. p. 2014. ID - ref1 ER - TY - STD TI - DeSantis CE, Siegel RL, Sauer AG, Miller KD, Fedewa SA, Alcaraz KI, et al. Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities. CA Cancer J Clin. 2016. ID - ref2 ER - TY - STD TI - McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017. ID - ref3 ER - TY - STD TI - Alizadeh AA, Aranda V, Bardelli A, Blanpain C, Bock C, Borowski C, et al. Toward understanding and exploiting tumor heterogeneity. Nat Med. 2015. ID - ref4 ER - TY - STD TI - Nowell PC. The clonal evolution of tumor cell populations. Science [Internet] 1976;194(4260):23–28. Available from: http://www.ncbi.nlm.nih.gov/pubmed/959840 UR - http://www.ncbi.nlm.nih.gov/pubmed/959840 ID - ref5 ER - TY - STD TI - Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res. 2012. ID - ref6 ER - TY - STD TI - Szerlip NJ, Pedraza A, Chakravarty D, Azim M, McGuire J, Fang Y, et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci. 2012. ID - ref7 ER - TY - STD TI - Liu X, George GC, Tsimberidou AM, Naing A, Wheler JJ, Kopetz S, et al. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. BMC Cancer. 2015. ID - ref8 ER - TY - STD TI - Gillies RJ, Flowers CI, Drukteinis JS, Gatenby RA. A unifying theory of carcinogenesis, and why targeted therapy doesn’t work. Eur J Radiol. 2012. ID - ref9 ER - TY - STD TI - Müller HM, Widschwendter A, Fiegl H, Ivarsson L, Goebel G, Perkmann E, et al. DNA methylation in serum of breast Cancer patients: an independent prognostic marker. Cancer Res. 2003. ID - ref10 ER - TY - STD TI - Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res. 1998. ID - ref11 ER - TY - STD TI - Jones PA. DNA methylation in development of bladder Cancer. Adv Bl Res. 1999:419–23. ID - ref12 ER - TY - STD TI - Lehmann U, Celikkaya G, Hasemeier B, Länger F, Kreipe H. Promoter hypermethylation of the death-associated protein kinase gene in breast cancer is associated with the invasive lobular subtype. Cancer Res. 2002. ID - ref13 ER - TY - STD TI - Branham MT, Marzese DM, Laurito SR, Gago FE, Orozco JI, Tello OM, et al. Methylation profile of triple-negative breast carcinomas. Oncogenesis. 2012. ID - ref14 ER - TY - STD TI - Kober P, Boresowicz J, Rusetska N, Maksymowicz M, Goryca K, Kunicki J, et al. DNA methylation profiling in nonfunctioning pituitary adenomas. Mol Cell Endocrinol. 2018. ID - ref15 ER - TY - STD TI - Campoy EM, Laurito SR, Branham MT, Urrutia G, Mathison A, Gago F, et al. Asymmetric cancer hallmarks in breast tumors on different sides of the body. PLoS One. 2016. ID - ref16 ER - TY - STD TI - Kiss NB, Kogner P, Johnsen JI, Martinsson T, Larsson C, Geli J. Quantitative global and gene-specific promoter methylation in relation to biological properties of neuroblastomas. BMC Med Genet. 2012. ID - ref17 ER - TY - STD TI - Kim M, Costello J. DNA methylation: an epigenetic mark of cellular memory. Experimental and Molecular Medicine. 2017. ID - ref18 ER - TY - STD TI - Mazor T, Pankov A, Song JS, Costello JF. Intratumoral heterogeneity of the epigenome. Cancer Cell. 2016. ID - ref19 ER - TY - STD TI - Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, Lau KW, et al. The life history of 21 breast cancers. Cell. 2012. ID - ref20 ER - TY - STD TI - Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012. ID - ref21 ER - TY - STD TI - Gao R, Davis A, McDonald TO, Sei E, Shi X, Wang Y, et al. Punctuated copy number evolution and clonal stasis in triple-negative breast cancer. Nat Genet. 2016. ID - ref22 ER - TY - STD TI - Lee J-Y, Yoon J-K, Kim B, Kim S, Kim MA, Lim H, et al. Tumor evolution and intratumor heterogeneity of an epithelial ovarian cancer investigated using next-generation sequencing. BMC Cancer. 2015. ID - ref23 ER - TY - STD TI - Venkatesan S, Swanton C. Tumor evolutionary principles: how Intratumor heterogeneity influences Cancer treatment and outcome. Am Soc Clin Oncol Educ B. 2016. ID - ref24 ER - TY - STD TI - Almendro V, Cheng YK, Randles A, Itzkovitz S, Marusyk A, Ametller E, et al. Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Rep. 2014. ID - ref25 ER - TY - JOUR AU - Marzese, D. M. AU - Gago, F. E. AU - Vargas-Roig, L. M. AU - Roqué, M. PY - 2010 DA - 2010// TI - Simultaneous analysis of the methylation profile of 26 cancer related regions in invasive breast carcinomas by MS-MLPA and drMS-MLPA JO - Mol Cell Probes VL - 24 UR - https://doi.org/10.1016/j.mcp.2010.05.002 DO - 10.1016/j.mcp.2010.05.002 ID - Marzese2010 ER - TY - STD TI - Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer [Internet] 2012;12(5):323–334. Available from: https://doi.org/10.1038/nrc3261%5Cnhttp://www.ncbi.nlm.nih.gov/pubmed/22513401 ID - ref27 ER - TY - STD TI - Yates LR, Gerstung M, Knappskog S, Desmedt C, Gundem G, Van Loo P, et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat Med. 2015. ID - ref28 ER - TY - STD TI - Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014;80. ID - ref29 ER - TY - STD TI - Janiszewska M, Liu L, Almendro V, Kuang Y, Paweletz C, Sakr RA, et al. In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. Nat Genet. 2015. ID - ref30 ER - TY - STD TI - Ennen M, Keime C, Kobi D, Mengus G, Lipsker D, Thibault-Carpentier C, et al. Single-cell gene expression signatures reveal melanoma cell heterogeneity. Oncogene. 2014. ID - ref31 ER - TY - STD TI - Irish JM, Hovland R, Krutzik PO, Perez OD, Bruserud Ø, Gjertsen BT, et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell. 2004. ID - ref32 ER - TY - STD TI - Singh DK, Ku CJ, Wichaidit C, Steininger RJ, Wu LF, Altschuler SJ. Patterns of basal signaling heterogeneity can distinguish cellular populations with different drug sensitivities. Mol Syst Biol. 2010. ID - ref33 ER - TY - STD TI - Brocks D, Assenov Y, Minner S, Bogatyrova O, Simon R, Koop C, et al. Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer. Cell Rep. 2014. ID - ref34 ER - TY - STD TI - Torres L, Ribeiro FR, Pandis N, Andersen JA, Heim S, Teixeira MR. Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases. Breast Cancer Res Treat. 2007. ID - ref35 ER - TY - STD TI - Park SY, Gönen M, Kim HJ, Michor F, Polyak K. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest. 2010. ID - ref36 ER - TY - JOUR AU - Moelans, C. B. AU - Verschuur-Maes, A. H. J. AU - Diest, P. J. PY - 2011 DA - 2011// TI - Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer JO - J Pathol VL - 225 UR - https://doi.org/10.1002/path.2930 DO - 10.1002/path.2930 ID - Moelans2011 ER - TY - STD TI - Friedlander TW, Roy R, Tomlins SA, Ngo VT, Kobayashi Y, Azameera A, et al. Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. Cancer Res. 2012. ID - ref38 ER - TY - STD TI - Zhao M, Zhao Z. Concordance of copy number loss and down-regulation of tumor suppressor genes: a pan-cancer study. BMC Genomics. 2016. ID - ref39 ER - TY - STD TI - Tostivint V, Racaud-Sultan C, Roumiguié M, Soulié M, Gamé X, Beauval J-B. Progress in prostate cancer study: 3D cell culture enables the ex vivo reproduction of tumor characteristics. Press Medicale. 2017. ID - ref40 ER - TY - STD TI - KHAN GN, KIM EJ, SHIN TS, LEE SH. Heterogeneous cell types in single-cell-derived clones of MCF7 and MDA-MB-231 cells. Anticancer Res. 2017. ID - ref41 ER - TY - STD TI - Harbst K, Lauss M, Cirenajwis H, Isaksson K, Rosengren F, Törngren T, et al. Multiregion whole-exome sequencing uncovers the genetic evolution and mutational heterogeneity of early-stage metastatic melanoma. Cancer Res. 2016. ID - ref42 ER - TY - STD TI - Dvorkin-Gheva A, Hassell JA. Identification of a novel luminal molecular subtype of breast cancer. PLoS One. 2014. ID - ref43 ER - TY - STD TI - Graf JF, Zavodszky MI. Characterizing the heterogeneity of tumor tissues from spatially resolved molecular measures. PLoS One. 2017. ID - ref44 ER - TY - STD TI - Cheng Y, Dai JY, Paulson TG, Wang X, Li X, Reid BJ, et al. Quantification of multiple tumor clones using gene array and sequencing data. Ann Appl Stat. 2017. ID - ref45 ER - TY - STD TI - Wang F, Dohogne Z, Jin Yang YL, Soibam B. Predictors of breast cancer cell types and their prognostic power in breast cancer patients. BMC genomics. 2018. ID - ref46 ER -